SI-BONE, Inc.(SIBN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,005 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SIBN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for SI-BONE, Inc. (SIBN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SIBN at 42.7/100 on a 32-signal composite quality model, placing it at rank #2,005 of 2,962 stocks — the bottom half of the AI-ranked universe. SIBN scores in the top quartile across institutional flow (85.3), revenue growth (81.2). Areas of concern include balance sheet strength (21.2) and free cash flow (23.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SI-BONE, Inc. reports quarterly revenue of $56.0M, net income of $-4.1M, an operating margin of -8.6%. Top institutional holders of SIBN by reported 13-F value include First Light Asset Management, BlackRock, CADIAN CAPITAL MANAGEMENT, based on the most recent SEC filings. SIBN trades on the Nasdaq exchange and files with the SEC under CIK 1459839. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SIBN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SI-BONE, Inc. directly from SEC EDGAR. SI-BONE, Inc.'s 13F Pro composite quality score has ranged between 23 and 43 since 2021, currently 42.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$56.0M
Net Income
Q2 2026
$-4.1M
Free Cash Flow
Q2 2026
$-768.0K
Operating Margin
Q2 2026
-8.6%
ROIC
Q2 2026
-8.8%
D/E Ratio
Q2 2026
0.20
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.2% YoYNet Income
+38.8% YoYOperating Income
+36.6% YoYEPS (Diluted)
+41.3% YoYTotal Assets
+3.5% YoYTotal Debt
+0.3% YoYOp. Cash Flow
+94.6% YoYFree Cash Flow
+60.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $200.9M +20.2% | $167.2M +20.4% | $138.9M +30.5% | $106.4M +18.0% | $90.2M +22.8% | $73.4M |
| Net Income | $-18.9M +38.8% | $-30.9M +28.7% | $-43.3M +29.3% | $-61.3M -8.3% | $-56.6M -29.5% | $-43.7M |
| Operating Income | $-22.3M +36.6% | $-35.2M +24.9% | $-46.9M +21.3% | $-59.6M -15.4% | $-51.7M -34.0% | $-38.6M |
| EPS (Diluted) | $-0.44 +41.3% | $-0.75 +33.6% | $-1.13 +36.9% | $-1.79 -4.7% | $-1.71 -14.0% | $-1.50 |
| Total Assets | $238.6M +3.5% | $230.4M +0.0% | $230.4M +46.3% | $157.6M -17.3% | $190.5M -14.6% | $223.1M |
| Total Debt | $35.6M +0.3% | $35.5M -1.7% | $36.1M +2.5% | $35.2M +0.6% | $35.0M -11.4% | $39.5M |
| Operating Cash Flow | $-675.0K +94.6% | $-12.4M +33.6% | $-18.7M +55.1% | $-41.7M -5.4% | $-39.5M -28.9% | $-30.7M |
| Free Cash Flow | $-9.1M +60.3% | $-22.9M +13.5% | $-26.5M +48.2% | $-51.2M -11.4% | $-45.9M -38.2% | $-33.2M |
Get alerted when SIBN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SI-BONE, Inc. including:
Top Institutional Holders of SIBN
First Light Asset Management, LLC
$132.6M8,127,985 shBlackRock, Inc.
$60.0M3,676,259 shCADIAN CAPITAL MANAGEMENT, LP
$54.6M3,347,574 shAMERICAN CENTURY COMPANIES INC
$41.0M2,510,963 shBROWN ADVISORY INC
$33.9M2,077,134 shGranahan Investment Management, LLC
$31.5M1,931,182 shVANGUARD CAPITAL MANAGEMENT LLC
$30.0M1,838,499 shImpax Asset Management Group plc
$23.3M1,425,010 shGILDER GAGNON HOWE & CO LLC
$20.4M1,253,042 shPARADIGM CAPITAL MANAGEMENT INC/NY
$20.1M1,233,200 sh
| Fund | Value | Shares |
|---|---|---|
| First Light Asset Management, LLC | $132.6M | 8,127,985 |
| BlackRock, Inc. | $60.0M | 3,676,259 |
| CADIAN CAPITAL MANAGEMENT, LP | $54.6M | 3,347,574 |
| AMERICAN CENTURY COMPANIES INC | $41.0M | 2,510,963 |
| BROWN ADVISORY INC | $33.9M | 2,077,134 |
| Granahan Investment Management, LLC | $31.5M | 1,931,182 |
| VANGUARD CAPITAL MANAGEMENT LLC | $30.0M | 1,838,499 |
| Impax Asset Management Group plc | $23.3M | 1,425,010 |
| GILDER GAGNON HOWE & CO LLC | $20.4M | 1,253,042 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | $20.1M | 1,233,200 |
Companies Similar to SIBN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NeuroPace Inc
Axogen, Inc.
ARTIVION, INC.
OmniAb, Inc.
Adaptive Biotechnologies Corp
Xeris Biopharma Holdings, Inc.
AtriCure, Inc.
GLAUKOS Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SIBN on your watchlist
Track score changes the day SI-BONE, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SIBN a good stock to buy?
13F Pro's AI-powered analysis of SI-BONE, Inc. (SIBN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SIBN are available on the SIBN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SIBN is classified as a small company.
Which hedge funds own SIBN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SIBN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SI-BONE, Inc.'s investment landscape.